🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

LFWD LFWD

Company Profile ↓
$7.25
-13.69% 1Y
P/E-0.42
52W High$9.94
52W Low$4.60
EPS (TTM)$-17.16

Company Overview

LFWD (LFWD) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Recent Developments

  • Dec 2025 Revenue of $1.40M (-17.6% YoY); net profit $-19.91M.
  • Trailing 12 Months Year-on-year growth — revenue -17.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR -1.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-1.04%
1 Year:-17.65%

Stock Price Performance

1 Year:-13.69%
6 Months:+5.07%
3 Months:+3.57%
1 Month:-14.20%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 50% of range
$4.60 $9.94
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)47.14 · Neutral
Price Performance
1M-14.20%
3M+3.57%
6M+5.07%
1Y-13.69%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -1.0% CAGR over 5 years.
  • Trading 27.0% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.42
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-1.04%
Profit 5Y
-
Revenue (YoY)
-17.65%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-86.96%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-6.70
EPS (TTM)
$-17.16

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$33.42M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
47.45%
Chg in Prom Hold
-
FII / Inst Holding
0.79%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$1.40M
EBITDA
-
Free Cash Flow
$-16.84M
Operating Cash Flow
$-16.83M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ------------------191.00K--123.00K--128.00K--489.00K--500.00K--443.00K
Gross Profit 33.00K60.00K87.00K493.00K85.00K290.00K1.05M741.00K708.00K682.00K767.00K762.00K926.00K435.00K649.00K373.00K1.02M392.00K707.00K727.00K1.14M265.00K746.00K221.00K571.00K576.00K863.00K1.40M2.76M2.22M2.12M2.51M2.71M1.34M
Operating Income -5.52M-5.84M-6.30M-6.42M-8.59M-7.40M-5.66M-5.37M-5.35M-5.84M-5.28M-4.12M-3.58M-4.24M-3.03M-3.60M-2.55M-3.07M-3.02M-3.14M-2.66M-4.29M-4.38M-5.43M-4.38M-5.16M-7.94M-6.50M-4.44M-3.17M-4.85M-6.56M-3.14M-10.34M
Net Income -5.71M-5.81M-6.39M-6.92M-9.12M-7.92M-6.40M-6.31M-5.85M-6.33M-5.80M-4.53M-4.00M-4.59M-3.39M-3.84M-2.85M-3.34M-3.06M-3.14M-2.67M-4.35M-4.45M-5.46M-4.32M-4.64M-7.53M-6.28M-4.30M-3.08M-4.83M-6.56M-3.17M-10.79M
Diluted EPS --------------------0.07-0.06-0.07-0.07-0.09-0.51-0.55-0.88-0.73-0.50-0.35-5.53-0.58-0.20-6.70
R&D Expense 1.54M1.45M1.26M1.70M3.07M1.97M1.43M1.39M1.62M2.15M1.90M1.60M1.41M1.86M1.02M985.00K954.00K756.00K795.00K810.00K638.00K907.00K956.00K1.06M752.00K816.00K1.26M1.29M1.21M998.00K918.00K767.00K721.00K5.84M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.59M3.95M3.75M5.87M135.00K6.54M4.87M330.00K432.00K352.00K435.00K1.70M1.40M
Gross Profit -429.00K-621.00K214.00K736.00K3.10M2.83M2.73M2.19M2.90M1.91M4.45M8.22M8.43M
Operating Income -8.74M-19.93M-25.17M-30.44M-21.99M-19.21M-14.05M-12.00M-12.65M-19.10M-23.61M-29.35M-19.67M
Net Income -12.18M-21.67M-25.41M-32.50M-24.72M-21.68M-15.55M-12.98M-12.74M-19.57M-22.13M-28.94M-19.91M
Diluted EPS --------0.82-0.27-2.20-31.13-39.96-17.16
R&D Expense 2.46M8.56M5.94M9.03M6.04M7.35M5.35M3.46M2.94M4.03M4.15M4.62M3.25M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --47.66M25.57M31.76M22.86M14.96M24.37M28.07M94.75M74.24M63.19M30.49M22.90M
Total Equity -2.26M5.63M43.85M20.92M8.26M3.71M1.95M10.78M21.77M89.38M68.17M46.51M18.85M8.41M
Cash & Equivalents 769.00K8.86M41.83M17.87M23.68M14.57M9.55M16.25M20.35M88.34M67.90M28.08M6.75M2.17M
Long Term Debt ---010.52M8.91M6.96M1.53M------
Total Liabilities --3.81M4.65M23.50M19.16M13.02M13.59M6.29M5.37M6.07M16.68M11.64M14.49M
Current Liabilities --3.57M4.34M12.40M9.73M5.38M10.17M4.67M4.04M4.78M11.79M10.22M12.04M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----26.75M-22.46M-14.77M-14.81M-12.59M-11.47M-17.89M-20.67M-21.72M-16.83M
Investing Cash Flow ----437.00K-21.00K-13.00K-22.00K-73.00K-47.00K-25.00K-18.15M0-16.00K
Financing Cash Flow ---33.78M13.41M9.71M21.48M16.72M79.51M-2.50M-992.00K012.20M
Capital Expenditure -187.00K-169.00K-584.00K-452.00K-21.00K-13.00K-22.00K-73.00K-47.00K-25.00K-81.00K-0-16.00K
Free Cash Flow ----27.20M-22.48M-14.79M-14.84M-12.66M-11.52M-17.92M-20.75M-21.72M-16.84M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -27.0%-15.7%5.7%12.5%2,297.0%43.2%55.9%663.3%672.0%541.2%1,023.7%483.3%602.0%
Operating Margin % -550.7%-504.3%-672.0%-518.7%-16,290.4%-293.6%-288.3%-3,637.6%-2,929.4%-5,426.7%-5,428.0%-1,726.3%-1,405.3%
Net Margin % -766.8%-548.4%-678.5%-553.8%-18,308.9%-331.2%-319.1%-3,932.1%-2,948.1%-5,559.4%-5,088.0%-1,702.5%-1,422.4%
ROE % -216.2%-49.4%-121.5%-393.5%-666.8%-1,114.4%-144.3%-59.6%-14.2%-28.7%-47.6%-153.5%-236.8%
ROCE % --45.2%-118.6%-157.2%-167.4%-200.6%-98.9%-51.3%-14.0%-27.5%-45.9%-144.8%-181.1%

Shareholding Pattern

Insiders
47.45%
Institutions
0.79%
Public Float
1.50%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LFWD

Yahoo Finance Wed, 05 Aug 2026

Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton

Ottobock Care, one of the leading mobility technology patient care organizations in the U.S., brings extensive clinical expertise and patient care infrastructure Advances Lifeward’s strategy to broaden ReWalk access through capital-efficien…

Yahoo Finance ue, 21 Jul 2026

Nano Dimension Announces Appointment of Interim Chief Executive Officer and Chairman of the Board

WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano”, or the “Company”) today announced the appointment of Moshe Rozenbaum as Interim Chief Executive Officer (“CEO”), effective immed…

Yahoo Finance ue, 07 Jul 2026

Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing

Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestonesHUDSON, Mass. an…

Yahoo Finance ue, 19 May 2026

Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform

Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward’s continued i…

Yahoo Finance Sun, 17 May 2026

How The Lifeward (LFWD) Story Is Shifting With New Price Targets And Valuation Assumptions

Lifeward’s analyst price target has shifted to US$10, prompting a closer look at what is driving this new reference point for the stock. Analysts link the change to updates in their fair value frameworks, which now align the US$10 target wi…

Yahoo Finance Fri, 15 May 2026

Lifeward Ltd (LFWD) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing Growth ...

Lifeward Ltd (LFWD) reports a revenue dip amid supply chain issues but strengthens its position with strategic acquisitions and financing.

LFWD — Frequently Asked Questions

What is the current share price of LFWD?

As of 2026-08-05 17:25 PDT, LFWD trades at $7.25 on NASDAQ/NYSE. Its 52-week range is $4.60 to $9.94.

What is the P/E ratio of LFWD?

LFWD trades at a trailing price-to-earnings (P/E) ratio of -0.42.

Is LFWD a good stock to buy?

This page provides a data-driven analysis of LFWD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space